Everest Medicines Appoints Two mRNA Cancer Vaccine Scientists
Everest Medicines has appointed two experienced mRNA cancer vaccine scientists, formerly of Moderna, to advance its global clinical development. The hires support the progression of the company's mRNA programs.
HONGKONG – Everest Medicines has bolstered its scientific leadership by appointing two veteran mRNA cancer vaccine scientists. Lakshmi Srinivasan, PhD, and Brandon Coder, PhD, have both joined the company from Moderna, a leader in mRNA technology.
Srinivasan, previously Executive Director and Head of Oncology Translational Medicine at Moderna, and Coder, former Research & Early Translational Lead, Cancer Vaccines at Moderna, bring extensive expertise to Everest Medicines' efforts to advance global clinical development. Their appointments are expected to enhance the company's capabilities in the rapidly evolving field of cancer immunotherapy.
The move aligns with Everest Medicines' strategy to develop treatments for significant unmet medical needs across Asia and globally. The company aims to leverage cutting-edge scientific knowledge to accelerate drug development timelines and bring novel therapies to patients faster.
Everest Medicines stated that the new recruits will support the advancement of its existing mRNA-based cancer vaccine programs and the exploration of new therapeutic candidates. The company is focused on improving outcomes for cancer patients through innovative approaches.